Our finding of angiogenesis inhibition was in line with a previous study [13] that used a bladder tumor model, which demonstrated that IFNβ-AF-MSC treatment resulted in a reduction in vascularization. The gene discussed is IFNB1; the disease is urinary bladder neoplasm.